Literature DB >> 22764107

Immune thrombocytopenia: getting back to basics.

Donald M Arnold1.   

Abstract

Entities:  

Mesh：

Year:  2012        PMID： 22764107      PMCID： PMC4854618          DOI： 10.1002/ajh.23287

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  21 in total

1.  Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings.

Authors:  G K Lo; D Juhl; T E Warkentin; C S Sigouin; P Eichler; A Greinacher
Journal:  J Thromb Haemost       Date:  2006-04       Impact factor: 5.824

2.  A pilot randomized trial of adjuvant rituximab or placebo for nonsplenectomized patients with immune thrombocytopenia.

Authors:  Donald M Arnold; Nancy M Heddle; Julie Carruthers; Deborah J Cook; Mark A Crowther; Ralph M Meyer; Yang Liu; Richard J Cook; Anne McLeod; Janet A MacEachern; Joy Mangel; David Anderson; Linda Vickars; Alan Tinmouth; Andre C Schuh; John G Kelton
Journal:  Blood       Date:  2012-01-05       Impact factor: 22.113

3.  Prevalence of diagnosed adult immune thrombocytopenia in the United Kingdom.

Authors:  Dimitri Bennett; M Elizabeth Hodgson; Amit Shukla; John W Logie
Journal:  Adv Ther       Date:  2011-12-01       Impact factor: 3.845

Review 4.  Piecing together the humoral and cellular mechanisms of immune thrombocytopenia.

Authors:  Lisa J Toltl; Ishac Nazi; Reza Jafari; Donald M Arnold
Journal:  Semin Thromb Hemost       Date:  2011-11-18       Impact factor: 4.180

5.  Prevalence of diagnosed chronic immune thrombocytopenic purpura in the US: analysis of a large US claim database: a rebuttal.

Authors:  M A Feudjo-Tepie; N J Robinson; D Bennett
Journal:  J Thromb Haemost       Date:  2008-01-21       Impact factor: 5.824

6.  Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group.

Authors:  Francesco Rodeghiero; Roberto Stasi; Terry Gernsheimer; Marc Michel; Drew Provan; Donald M Arnold; James B Bussel; Douglas B Cines; Beng H Chong; Nichola Cooper; Bertrand Godeau; Klaus Lechner; Maria Gabriella Mazzucconi; Robert McMillan; Miguel A Sanz; Paul Imbach; Victor Blanchette; Thomas Kühne; Marco Ruggeri; James N George
Journal:  Blood       Date:  2008-11-12       Impact factor: 22.113

Review 7.  The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia.

Authors:  Cindy Neunert; Wendy Lim; Mark Crowther; Alan Cohen; Lawrence Solberg; Mark A Crowther
Journal:  Blood       Date:  2011-02-16       Impact factor: 22.113

8.  Accuracy of clinical assessment of deep-vein thrombosis.

Authors:  P S Wells; J Hirsh; D R Anderson; A W Lensing; G Foster; C Kearon; J Weitz; R D'Ovidio; A Cogo; P Prandoni
Journal:  Lancet       Date:  1995-05-27       Impact factor: 79.321

9.  Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study.

Authors:  Gregory Cheng; Mansoor N Saleh; Claus Marcher; Sandra Vasey; Bhabita Mayer; Manuel Aivado; Michael Arning; Nicole L Stone; James B Bussel
Journal:  Lancet       Date:  2010-08-23       Impact factor: 79.321

10.  Prevalence of immune thrombocytopenia: analyses of administrative data.

Authors:  J B Segal; N R Powe
Journal:  J Thromb Haemost       Date:  2006-07-27       Impact factor: 5.824
View more
  3 in total

Review 1.  Severe bleeding events in adults and children with primary immune thrombocytopenia: a systematic review.

Authors:  C Neunert; N Noroozi; G Norman; G R Buchanan; J Goy; I Nazi; J G Kelton; D M Arnold
Journal:  J Thromb Haemost       Date:  2015-01-14       Impact factor: 5.824

2.  A novel canine model of immune thrombocytopenia: has immune thrombocytopenia (ITP) gone to the dogs?

Authors:  Dana N LeVine; Adam J Birkenheuer; Marjory B Brooks; Shila K Nordone; Dwight A Bellinger; Sam L Jones; Thomas H Fischer; Stephen E Oglesbee; Kahlina Frey; Nicole S Brinson; Allison P Peters; Henry S Marr; Alison Motsinger-Reif; Sif Gudbrandsdottir; James B Bussel; Nigel S Key
Journal:  Br J Haematol       Date:  2014-07-08       Impact factor: 6.998

3.  Efficacy and safety of rituximab as second-line therapy in immune thrombocytopenic purpura based on ethnicity: A descriptive study among the Arabic population.

Authors:  Fateen Ata; Zohaib Yousaf; Fathima Z Zahir; Anas Mohamed Babiker; Amer Ali Farooqi; Mousa Ahmad Al Hiyari; Adel Issam Al Bozom; Ahmed Hatim Mohamed; Abdulqadir J Nashwan; Mohamed A Yassin
Journal:  Qatar Med J       Date:  2022-07-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.